14-3-3Σ Promotes HCC Anoikis Resistance Through Inhibiting EGFR Degradation and Regulating Activation of EGFR-Dependent ERK Signalling Pathway
Jia Song,Yachong Liu,Furong Liu,Lu Zhang,Ganxun Li,Chaoyi Yuan,Chengpeng Yu,Xu Lu,Qiumeng Liu,Huifang Liang,Zeyang Ding,Bixiang Zhang
DOI: https://doi.org/10.2139/ssrn.3502346
2019-01-01
Abstract:Background: Metastasis contributes to the poor prognosis of hepatocellular carcinoma (HCC). Anoikis resistance is acquired during tumor progression. 14-3-3σ is implicated in the development of chemo and radiation resistance and in poor prognosis of multiple human cancers. However, its function in anoikis resistance and metastasis in HCC is currently unknown.Methods: In HCC tissue sample pairs, 14-3-3σ protein levels were measured by Western blot and immunohistochemical (IHC) staining, respectively. Statistical analysis was performed to evaluate the clinical correlation between 14-3-3σ expression and clinicopathological features, and overall survival. Artificial modulation of 14-3-3σ (down- and over-expression) was performed to explore the role of 14-3-3σ in HCC anoikis resistance and tumor metastasis in vitro and in vivo. Association of 14-3-3σ with epidermal growth factor receptor (EGFR) was assayed by co-immunoprecipitation. Effects of 14-3-3σ ectopic expression or knockdown on EGFR signaling activation, ligand-induced EGFR degradation and ubiquitination were examined using Immunoblotting and co-immunoprepiation, immunofluorescent staining, and flow cytometry analysis. The levels of EGFR ubiquitination, the interaction between EGFR and 14-3-3σ, and the association of EGFR with c-Cbl after EGF stimulation, in 14-3-3σ ectopic expression or knockdown cells were examined to elucidate the mechanism by which 14-3-3σ inhibits EGFR degradation. Using gain-of-function or loss-of-function strategies, we further investigated the role of EGFR signaling pathway and its downstream target machinery in 14-3-3σ-mediated resistance to anoikis of HCC cells.Findings: We found that 14-3-3σ was up-regulated in HCC tissues and its level was positively correlated to aggressive clinicopathologic features and poor survival of patients with HCC. In vitro and in vivo studies indicate 14-3-3σ promotes anoikis resistance and metastasis of HCC cells. Mechanistically, we showed that 14-3-3σ could interact with EGFR and significantly inhibited EGF-induced degradation of EGFR, sustained activated receptor, and therefore prolonged activation of EGFR signaling. Our studies revealed that overexpression of 14-3-3σ resulted in inhibition of EGFR ubiquitination, while knockdown of 14-3-3σ led to an increase in EGFR ubiquitination in HCC cells. We demonstrated that 14-3-3σ inhibited ligand-induced EGFR degradation through inhibiting EGFR-c-Cbl association and subsequent c-Cbl-mediated EGFR ubiquitination. We further verified that ERK pathway activation was responsible for 14-3-3σ-mediated resistance to anoikis of HCC cells. Moreover, EGFR inactivation reversed the 14-3-3σ-mediated effects on ERK phosphorylation and anoikis resistance.Interpretation: Our results indicate that 14-3-3σ plays a pivotal role in HCC cell anoikis resistance and metastasis presumably by inhibiting EGFR degradation and regulating activation of the EGFR-dependent ERK pathway. This is the first report of the role of 14-3-3σ in the anoikis resistance of HCC cells, and it may pave way for manipulation of metastatic cancer by targeting 14-3-3σ.Funding Statement: This work was supported by grants from the National Natural Science Foundation of China (No. 81372327, No. 81572427 to Bixiang Zhang; No. 81202300 to Huifang Liang).Declaration of Interests: The authors declare no conflict of interest.Ethics Approval Statement: Ethical approval was obtained from the Ethical Committee of Tongji Hospital, Huazhong University of Science and Technology (HUST). All patients provided written informed consent for use of their tissue specimens. The study methodologies conformed to be standards set by the Declaration of Helsinki.All of the animal studies met the National Institutes of Health guidelines (NIH publication 86-23 revised 1985), and were approved by the Committee on the Ethics of Animal Experiments of the Tongji Medical College, HUST.